Publications by authors named "Y J Kawamura"
Recently, the anti-programmed cell death protein 1 antibody pembrolizumab, a type of immune checkpoint inhibitor (ICI), has been used in preoperative systemic chemotherapy for hormone receptor and human epidermal growth factor 2-negative breast cancer, also known as triple-negative breast cancer (TNBC). Chemotherapy with pembrolizumab has demonstrated clinical activity in terms of pathologic complete response and event-free survival. Despite their efficacy, the current understanding of the full spectrum of side effects associated with relatively new ICIs remains incomplete.
View Article and Find Full Text PDFSpontaneous rupture of renal cell carcinoma (RCC) occurs in 0.3-0.6% of all RCC cases.
View Article and Find Full Text PDFArticle Synopsis
- This systematic review and meta-analysis assessed how enhanced rehabilitation after hospital discharge affects the quality of life (QOL) for survivors of critical care, following PRISMA guidelines and examining data from several major health databases until January 2024.
- The review included nine randomized controlled trials (RCTs) with 573 participants, finding that enhanced rehabilitation showed no significant improvement in physical QOL but did result in a higher mental QOL score (low-certainty evidence).
- Adverse events' impact was uncertain, with mixed reports from the studies; some had no adverse events, while others noted serious incidents, indicating very low-certainty evidence on this issue.
Background: This case series evaluated the clinical impact and significant technical points of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the smaller drug-eluting bead (DEB) M1 (DC Bead M1; 70-150 µm).
Methods: We evaluated 12 patients and 14 HCC nodules treated with DEB-TACE using the DC Bead M1 (named DEM1-TACE). In addition to evaluating the early treatment efficacy for each treated node after DEM1-TACE, the study also used interventional radiology (IVR)- computed tomography (CT) to focus on the presence or absence of retention of the homogeneous contrast medium in target nodules after DEM1-TACE as a predictor of a good treatment response.